CMC(SH:603122)2024-03-22 16:00Financial Performance - The company's operating revenue for 2023 was approximately ¥1.09 billion, a decrease of 14.62% compared to ¥1.28 billion in 2022[24]. - Net profit attributable to shareholders decreased by 42.96% to approximately ¥47.19 million in 2023 from ¥82.72 million in 2022[24]. - Basic earnings per share fell by 45.45% to ¥0.12 in 2023, down from ¥0.22 in 2022[24]. - The weighted average return on equity decreased by 3.50 percentage points to 4.06% in 2023 from 7.56% in 2022[24]. - The total revenue for the year reached ¥1,092,272,353.17, representing a year-on-year increase of 20.70%[59]. - The operating income from the medical product circulation segment decreased significantly by 72.13% year-on-year, amounting to ¥57,426,153.35[59]. - The gross profit margin for the medical product circulation segment was reported at 26.55%, down by 12.23 percentage points compared to the previous year[59]. - The company reported a total revenue of 1,092,602,026.63 RMB for the reporting period, a decrease of 14.62% compared to the previous year[54]. - The net profit attributable to shareholders was 47,186,900 RMB, reflecting a significant decline of 42.96% year-over-year[54]. Cash Flow and Assets - The net cash flow from operating activities improved to approximately ¥11.28 million in 2023, compared to a negative cash flow of ¥30.37 million in 2022[24]. - The total assets at the end of 2023 were approximately ¥1.46 billion, a decrease of 6.26% from ¥1.56 billion at the end of 2022[24]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥1.17 billion, a slight decrease of 0.93% from ¥1.18 billion at the end of 2022[24]. - The total operating costs for the year were ¥866,158,543.42, a reduction from ¥1,021,774,257.93 in the previous year[63]. - The net cash flow from operating activities was ¥11,281,136.90, a significant improvement from a negative cash flow of ¥30,366,164.41 in the same period last year[75]. Strategic Initiatives and Future Outlook - The company aims to achieve approximately CNY 1.248 billion in revenue and a net profit of around CNY 79 million for the year 2024[96]. - The company plans to enhance customer loyalty by providing differentiated empowerment services and expanding its customer base[96]. - The company will focus on expanding its marketing network nationwide, particularly in regions where it has not yet established operations[92]. - The company is committed to optimizing and upgrading its centralized procurement services for in vitro diagnostic reagents and consumables[91]. - The company plans to enhance its digital marketing efforts, allocating an additional 2 million to boost online presence and engagement[113]. Corporate Governance and Compliance - The company has established a complete independent financial accounting system and internal control measures, ensuring financial independence from the controlling shareholder[106]. - The company has received a standard unqualified opinion on the effectiveness of its internal control from KPMG Huazhen, indicating robust internal control practices[146]. - The company has not experienced any major legal violations or penalties during the reporting period[105]. - The company has established an independent organizational structure, ensuring that the shareholders' meeting, board of directors, and supervisory board operate independently without interference from controlling shareholders[107]. - The company has no actual controller, leading to potential instability in governance and operational decision-making risks[98]. Social Responsibility and Community Engagement - The company has actively engaged in social responsibility initiatives, with total donations amounting to ¥90.13 million, including ¥52.87 million in cash and ¥37.26 million in material contributions[155]. - The company committed to supporting national poverty alleviation and rural revitalization efforts, donating ¥60,000 to improve educational opportunities for underprivileged youth[156]. - The company donated medical clinical testing equipment and reagents to 8 hospitals in Guanghe County, benefiting approximately 200-500 patients[157]. - The company aims to continue leveraging its resources to support social welfare and rural revitalization as part of its corporate social responsibility[157]. Research and Development - Research and development expenses increased by 13.70% to 3,182,530.27 RMB, indicating a focus on innovation and new product development[55]. - The company is investing heavily in R&D for new technologies, with a budget allocation of 10 million for the upcoming year[113]. - The company has 9 R&D personnel, accounting for 3.75% of the total workforce, with 1 holding a master's degree and 8 holding bachelor's degrees[71]. Shareholder Matters and Dividends - The board proposed a cash dividend of CNY 0.60 per share, totaling approximately CNY 23.88 million, pending shareholder approval[6]. - The company has a cash dividend policy that stipulates a minimum of 10% of the distributable profit will be distributed as cash dividends if conditions are met[135]. - The total dividend amount (including tax) is ¥23,883,157.98, which also represents 50.61% of the consolidated net profit attributable to ordinary shareholders[142]. - The company’s profit distribution plan requires a two-thirds majority approval from shareholders at the general meeting[137].